延长蒿甲醚-苯芴醇疗程对乌干达无并发症疟疾患儿抗疟药物暴露及再感染风险的影响:一项随机对照试验
在乌干达高传播地区开展前瞻性随机开放标签药代动力学/药效学研究,177名16月龄至16岁疟疾患儿随机接受3天(标准6剂)或5天(10剂)蒿甲醚-苯芴醇方案,共227次发作。5天方案显著提高第7、14、21天末期中位苯芴醇浓度(P<.001),但28天(51% vs 40%)和42天(75% vs 68%)复发风险无显著差异;延长疗程未见显著毒性。
要点
- 5天蒿甲醚-苯芴醇方案显著提高第7、14、21天苯芴醇浓度(P<.001),但未显著降低复发风险。
- 第7天苯芴醇浓度280 ng/mL阈值对28天和42天复发风险有强预测作用(P<.001)。
- 最低体重组患儿接受标准3天方案时给药不足风险更高。
核心结论
- 延长蒿甲醚-苯芴醇疗程安全且显著提高幼儿总体药物暴露,但在高传播地区未显著降低复发疟疾风险。
- 第7天苯芴醇水平对复发风险有强预测作用,最低体重组患儿接受标准3天方案时给药不足风险更高。
研究设计与样本
- 前瞻性、随机、开放标签药代动力学/药效学研究,在乌干达高传播农村地区开展。
- 177名16月龄至16岁疟疾患儿随机接受3天(标准6剂)或5天(10剂)蒿甲醚-苯芴醇方案,共227次发作。
- 对蒿甲醚、双氢青蒿素和苯芴醇进行采样,临床随访42天。
主要发现
- 5天方案组第7、14、21天末期中位苯芴醇浓度显著高于3天方案组(P<.001)。
- 预设第7天苯芴醇阈值280 ng/mL对28天和42天复发风险有强预测作用(P<.001)。
- Kaplan-Meier估计28天复发风险3天方案组51% vs 5天方案组40%,42天复发风险3天方案组75% vs 5天方案组68%,均无显著差异。
- 延长方案未见显著毒性。
关键数值与推荐
- 5天方案组第7、14、21天末期中位苯芴醇浓度显著高于3天方案组(P<.001)。
- 第7天苯芴醇阈值280 ng/mL对28天和42天复发风险有强预测作用(P<.001)。
- 28天复发风险:3天方案组51% vs 5天方案组40%,无显著差异。
- 42天复发风险:3天方案组75% vs 5天方案组68%,无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Artemether-lumefantrine (AL) is the most widely used artemisinin-based combination therapy in Sub-Saharan Africa and is threatened by the emergence of artemisinin resistance. Dosing is suboptimal in young children. We hypothesized that extending AL duration will improve exposure and reduce reinfection risks. METHODS: We conducted a prospective, randomized, open-label pharmacokinetic/pharmacodynamic study of extended duration AL in children with malaria in high-transmission rural Uganda. Children received 3-day (standard 6-dose) or 5-day (10-dose) AL with sampling for artemether, dihydroartemisinin, and lumefantrine over 42-day clinical follow-up. Primary outcomes were (1) comparative pharmacokinetic parameters between regimens and (2) recurrent parasitemia analyzed as intention-to-treat. RESULTS: A total of 177 children aged 16 months to 16 years were randomized, contributing 227 total episodes. Terminal median lumefantrine concentrations were significantly increased in the 5-day versus 3-day regimen on days 7, 14, and 21 (P < .001). A predefined day 7 lumefantrine threshold of 280 ng/mL was strongly predictive of recurrence risk at 28 and 42 days (P < .001). Kaplan-Meier estimated 28-day (51% vs 40%) and 42-day risk (75% vs 68%) did not significantly differ between 3- and 5-day regimens. No significant toxicity was seen with the extended regimen. CONCLUSIONS: Extending the duration of AL was safe and significantly enhanced overall drug exposure in young children but did not lead to significant reductions in recurrent parasitemia risk in our high-transmission setting. However, day 7 levels were strongly predictive of recurrent parasitemia risk, and those in the lowest weight-band were at higher risk of underdosing with the standard 3-day regimen. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov number NCT03453840.
引用
- Whalen ME, Kajubi R, Goodwin J, et al. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial. Clin Infect Dis. 2023. PMID: 36130191. doi:10.1093/cid/ciac783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。